Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Status:
Completed
Trial end date:
2019-08-08
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib and everolimus may stop the growth of cancer cells by blocking blood
flow to the cancer and by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I/II trial is studying the side effects and best dose of sorafenib and
everolimus and to see how well they work in treating patients with relapsed or refractory
non-Hodgkin's lymphoma, Hodgkin's lymphoma, or multiple myeloma.